Other News To Note
Monday, October 29, 2012
Pharmaxis Ltd., of Sydney, Australia, said the National Institute for Health and Clinical Excellence in the UK issued a positive recommendation in its final appraisal determination for Bronchitol (mannitol dry powder for inhalation), approved to treat adult cystic fibrosis patients as an add-on therapy to best standard of care.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.